Molecular Partners: Road to IPO and beyond

Date
03.10.2017 18:45 - 21:00
Location
Halle 7, Dornacherstrasse 192, Basel

Patrick Amstutz, CEO and co-founder of Molecular Partners, talks about the exciting story of Molecular Partners and shares lessons learned along the way.

Starting and financing a biotech company is not a piece of cake. But closing partnerships and progressively bigger financing rounds, bringing molecules into clinical development and eventually floating a company on the stock market is even harder. Molecular partners has done all of that. The biotech, which emanated out of research of the University of Zürich, is developing DARPins® therapeutics, a new class of small protein therapeutic agents, with high-specificity, potency and versatility in one therapy. The lead compound is partnered with Allergan and currently in phase III. And in 2014, the company successfully floated on the Swiss Stock Exchange.

Register/Details:

Show All

Events

28.02.2018 13:15 - 18:00

IFZ FinTech Konferenz Institut für Finanzdienstleistungen Zug IFZ

Show All

Trainings

27.02.2018 16:00 - 18:00

European Funding and Innovation Programs – Chances for SMEs Technopark Zurich, Room «Cobol»

Principal

Investors list

Startupticker has compiled a list of investors including business angel clubs, venture capitalists and corporate Venture capitalists, investment banks as well as business angels that are involved in financing rounds of startups from seed- to later stage and to growth stage investment.

Partners

Contributors